SPRINT-TB programme officially commenced in July 2014 and in slightly over a year of its existence has produced an array of research findings and achievements. Notable highlights in the first year of SPRINT-TB's formal existence include identification by Theme 1 of potent activity of bortezomib against a new target M. tuberculosis. In Theme 2, work has started on finding the derivatives of bortezomib that may have greater selectivity in killing bacteria with minimal toxicity.Theme 3 has established a platform for testing new drugs and combinations in humans - the whole blood bactericidal activity assay - and modified this to be able to test drugs that work against bacteria, as well as that modify the host immune response. Theme 4 has set up a collaborative effort in TB health services research with the national TB programme in Cambodia and opened the SPRINT-TB office in Phnom Penh.
SPRINT-TB Annual Report 2016/2017 is available for download here.